Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 31, 2026 10:04 ET | Source: Kaldvik AS

KALDVIK AS (KLDVK): Q1 2026 Quarterly Update

KALDVIK AS (KLDVK) reports Operating income in Q1 amounted to EURm 36.5 (EURm 48.4), while the operating loss before fair value adjustment of biomass and production tax was EURm -26.4 (EURm 9.8). ...
May 31, 2026 10:00 ET | Source: Precede Biosciences, Inc.

Precede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight™ to Decode MET-Driven Biology and Resistance in Advanced NSCLC

Data include assessment of MET expression, tumor and immune pathway activity, and lineage plasticity from just 1 mL of plasma in advanced NSCLCPlasma MET test showed high concordance with tissue...
May 31, 2026 09:25 ET | Source: James Altucher, Tech Investor

James Altucher Spent Months Researching the Technology Behind the SpaceX IPO. He Put Everything Into One Presentation and Released It for Free

Washington, D.C., May 31, 2026 (GLOBE NEWSWIRE) -- James Altucher says he has never spent this much time on a single presentation. The research behind it consumed months. The subject matter spans...
May 31, 2026 09:00 ET | Source: https://immatics.com/

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancerIn head and neck...
May 31, 2026 09:00 ET | Source: NEWMEDIA.COM

Why AI Visibility Operating Systems Are Replacing Fragmented Marketing Strategies

NEWMEDIA.COM explores why AI Visibility Operating Systems are replacing fragmented marketing strategies in AI-driven discovery environments.
May 31, 2026 08:39 ET | Source: Johnson & Johnson EMEA

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the...
May 31, 2026 08:25 ET | Source: AIX Alpha

AI Is Reshaping Crypto Faster Than Anyone Expected as AIX Alpha’s New System Signals the Shift

LOS ANGELES, May 31, 2026 (GLOBE NEWSWIRE) -- Crypto markets have been moving with a speed that’s catching many traders off guard. What used to be steady trend cycles has shifted into sudden, sharp...
May 31, 2026 08:06 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

REDWOOD CITY, Calif., May 31, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
May 31, 2026 08:00 ET | Source: Replimune, Inc.

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...
May 31, 2026 08:00 ET | Source: Immunocore Holdings plc

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease...